ADVI Analysis: MACPAC April 2024 Meeting

Pharmaceuticals and Biotech Federal And State Policy

April 15, 2024

MACPAC held a meeting April 11-12 (link). The following relevant topics were discussed

  • Medicaid Demographic Data Collection
  • Improving Transparency of Medicaid & CHIP Financing
  • Optimizing State Medicaid Agency Contracts
  • Vote on June Report and Lessons from Medicaid Unwinding

ADVI Angle

Key takeaways from the April meeting include:

  • Medicaid Demographic Data Collection
    • MACPAC staff presented on the need to improve Medicaid demographic data collection, primarily regarding language, sexual orientation and gender identity (SOGI), and disability. Commissioners were supportive of this work, making minor suggestions on improvement to ensure the highest quality data is collected.
  • Improving Transparency of Medicaid & CHIP Financing
    • MACPAC staff reviewed proposed recommendations that expand on prior recommendations to increase transparency of provider contributions in Medicaid financing for both Medicaid and CHIP. Commissioners voted unanimously to pass the draft recommendations.
  • Optimizing State Medicaid Agency Contracts
    • MACPAC staff presented proposed recommendations that build on previous recommendations to improve integration strategy and efficiency relating to State Medicaid Agency Contracts (SMACs). Commissioners reviewed a draft chapter on SMAC optimization and voted unanimously to pass both presented recommendations.
  • Lessons from Medicaid Unwinding
    • MACPAC staff held a panel featuring Medicaid experts to discuss the lessons learned from the Medicaid Unwinding process, and opportunities stakeholders and policymakers can explore to improve outcomes. Commissioners expressed heightened interest in improving processes relating to ex parte renewals, notices, and enrollee outreach.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.